Williams, 44, said that she made the decision after trying just about every other avenue
[1] [2] These medications include semaglutide (Ozempic, Wegovy, Rybelsus), dulaglutide (Trulicity), liraglutide (Victoza, Saxenda), and others
"Incretin triple agonist retatrutide (LY3437943) alleviates obesity-associated cancer progression"
This medicine turns on three main receptors
A BMI of 30 in a white individual carries equivalent diabetes risk to a BMI of approximately 23.9 in a South Asian individual and 26.9 in a Chinese individual
Current 2026 approved GLP-1 RA medications include semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound)